Home » Stocks » MIST

Milestone Pharmaceuticals Inc. (MIST)

Stock Price: $5.33 USD -0.13 (-2.29%)
Updated May 13, 2021 3:58 PM EDT - Market closed
Market Cap 169.34M
Revenue (ttm) n/a
Net Income (ttm) -49.97M
Shares Out 29.85M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $5.33
Previous Close $5.45
Change ($) -0.13
Change (%) -2.29%
Day's Open 5.46
Day's Range 5.19 - 5.65
Day's Volume 42,703
52-Week Range 2.95 - 11.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

If Milestone Pharmaceuticals' Etripamil nasal spray succeeds in clinical trials, MIST stock is going to see big growth. The post Milestone Pharmaceuticals Stock Is a Bet On Etripamil appeared first on I...

1 month ago - InvestorPlace

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...

1 month ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...

1 month ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Feb. 25, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...

2 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...

5 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...

6 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...

6 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Oct. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...

6 months ago - PRNewsWire

MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...

7 months ago - PRNewsWire

Milestone Pharmaceuticals offers a critical solution for those with an acute heart condition. However, it has a mixture of positives and negatives, making MIST stock a wild wager.

8 months ago - InvestorPlace

When a biotech firm focuses its efforts on one disease and one drug, the stakes are high. Still, the payoff could be huge with MIST stock.

8 months ago - InvestorPlace

MONTREAL and CHARLOTTE, N.C., Aug. 12, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.

9 months ago - PRNewsWire

Milestone Pharmaceuticals (MIST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

9 months ago - Zacks Investment Research

Milestone Pharmaceuticals (MIST) news for Thursday includes new guidelines for a clinical study pushing MIST stock higher.

9 months ago - InvestorPlace

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) shares more than doubled on Thursday after the company announced a key clinical and regulatory update.

9 months ago - 24/7 Wall Street

MONTREAL and CHARLOTTE, N.C., July 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc.

9 months ago - PRNewsWire

As of late, it has definitely been a great time to be an investor in Milestone Pharmaceuticals.

11 months ago - Zacks Investment Research

Milestone Pharmaceuticals (MIST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor of Milestone Pharmaceuticals

11 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for May 19th

Other stocks mentioned: AGFS, SYRS, UNFI
11 months ago - Zacks Investment Research

MONTREAL and CHARLOTTE, N.C., May 14, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...

11 months ago - PRNewsWire

Milestone Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Other stocks mentioned: AMAG, CPIX
1 year ago - Zacks Investment Research

Shares of small-cap Milestone Pharmaceuticals Inc (NASDAQ: MIST) were losing three-quarters of their value Tuesday on the back of a negative clinical readout.

1 year ago - Benzinga

Soon-to-be-released pivotal clinical trial results could send this drug developer’s stock skyward.

1 year ago - The Motley Fool

About MIST

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as in the Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate, and other cardiovascular indications. The company was incorporated in 2003 and is headquartered in Montréal, Canada... [Read more...]

Industry
Biotechnology
Founded
2003
Stock Exchange
NASDAQ
Ticker Symbol
MIST
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for MIST stock is "Buy." The 12-month stock price forecast is 14.40, which is an increase of 170.42% from the latest price.

Price Target
$14.40
(170.42% upside)
Analyst Consensus: Buy